Incubate executive director John Stanford was recently featured in a PharmaVoice  article by lead editor Meagan Parrish on Incubate's survey  of early-stage biotech CEOs. Respondents to Incubate's survey described  challenges to the biotech sector and cited a decline in investor interest due to regulatory pressures and other changes in Washington. The respondents' concerns included the Inflation Reduction Act's "pill penalty," tariffs on medicines, NIH funding cuts, and weake

In their new opinion piece for the Triangle Business Journal , Incubate executive director John Stanford and Patrick Jordan, managing...

Incubate's policy director John Guy recently sat down with Rep. Deborah Ross (D-N.C.) and several biotech executives for a roundtable...

Incubate, a coalition of life sciences investors, today unveiled the   Life Sciences Rare Disease Tracker , a tool designed to measure...

WASHINGTON (May 12) -- Today, President Trump signed an executive order to tie U.S. drug prices to the lowest prices paid in other...